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The goals of the project Social Cognition and Functioning 
in Schizophrenia (SCAF) were to (1) identify the domains 
to target from social neuroscience for translation to clini-
cal schizophrenia research, (2) identify the paradigms that 
represent these domains for which the neural substrates 
are well documented, (3) adapt these paradigms for use in 
schizophrenia clinical trials, (4) assess the psychometric 
properties of these measures, and (5) assess the external 
validity of these measures. The articles in this theme sec-
tion present the initial findings from the SCAF project. As 
more training and psychopharmacological studies evaluate 
interventions for social cognition, the articles in this theme 
section are intended to serve as a guide for informed design 
decisions about possible endpoints in clinical trials.
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Social cognition has emerged as an area of great interest 
for schizophrenia research. In fact, a search on PubMed 
with the terms social cognition, schizophrenia, and the 
year 2012 pulls up 303 articles on this topic. Numerous 
studies in this area have examined topics such as neural 
correlates of social cognitive activation tasks, patient-
control differences on measures from various social 
cognitive domains, links to daily functioning, and the 
commonalities and differences in social cognition across 
different psychiatric illnesses.
Social cognition has also become a treatment target in 
schizophrenia, as seen in the active development of novel 
training interventions,1–3 as well as attempts at pharmaco-
logical treatments.4–6 Treatment studies require critical deci-
sions about endpoints. To demonstrate a treatment effect 
for social cognition in a clinical trial, What measures should 
be used to show improvement? Are these measures reliable 
enough for clinical trials? Can they be repeated without 
compromising the results? Are they practical for multisite 
studies? and Are they linked to specific neural systems? For 
social cognition, these questions are largely unanswered.
An ongoing project funded by the National Institute 
of Mental Health (NIMH) entitled, Social Cognition and 
Functioning in Schizophrenia (SCAF) is attempting to 
address these questions. The goals of this project were to (1) 
identify the domains that are ripe for extensions from social 
neuroscience to clinical schizophrenia research, (2) iden-
tify the paradigms that tap these domains and for which 
the neural substrates are well documented, (3) adapt these 
paradigms for use in schizophrenia clinical trials, (4) assess 
the psychometric properties of these measures, and (5) 
assess the external validity of these measures (ie, their rela-
tionships to functionally meaningful variables). The SCAF 
project conceptually grows out of the NIMH Initiative, 
Cognitive Neuroscience for Treatment Research to Improve 
Cognition in Schizophrenia (CNTRICS).7 CNTRICS held 
a series of consensus meetings to identify the challenges in 
adapting measures from cognitive neuroscience and social 
neuroscience for use in clinical trials of schizophrenia.8 
A related project collected data on newly developed para-
digms from a subset of the CNTRICS domains, but social 
cognition and social neuroscience were not represented.9 
Hence, the SCAF project was designed to fill a large gap in 
the literature, starting with the articles in this theme section.
The paradigms examined in the SCAF project were 
considered to be novel for psychosis research—there had 
not been published studies in schizophrenia at the time 
the study started (see the following articles for complete 
descriptions of the domains and paradigms). In addition, 
they assess social cognitive subprocesses not covered 
by commonly used measures in psychosis research. The 
investigators on this project were under no illusions about 
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the difficulty of this translational approach. It is common 
for measures that work extremely well with college stu-
dents in the scanner to crash and burn when applied to 
chronically ill patients with psychotic disorders. There 
are many ways for such measures to fail, and among 
the most common are scaling problems (floor or ceiling 
effects), poor reliability (test-retest or inter-rater), prob-
lems with repeated assessments (eg, tasks that have an ah-
ha moment in which an answer is revealed), or feasibility 
(too long, too hard, or too dull).
A related project with an overlapping group of investiga-
tors, Social Cognition Psychometric Evaluation (SCOPE),10 
is evaluating the suitability of several existing social cogni-
tive measures for use in clinical trials. The primary goals of 
the SCOPE project are to achieve a consensus on the cur-
rent social cognitive domains studied in schizophrenia and 
to evaluate psychometric properties of existing measures to 
determine their suitability for clinical trials. The measures 
selected through the SCOPE project will differ from those 
in SCAF in several ways. First, they assess a particular sub-
set of social cognitive domains. Relevant areas of social 
processing are not covered, such as empathy, self-other 
processing, nonverbal/nonfacial emotion recognition, and 
automatic aspects of social processing. Second, the tasks 
did not come from social neuroscience, such as studies using 
functional magnetic resonance imaging and electrophysiol-
ogy. As a result, their neural substrates are typically unclear. 
Based on the different selection priorities, the SCOPE and 
SCAF projects are evaluating nonoverlapping sets of mea-
sures. With their emphases on existing measures (SCOPE) 
and adaptations from social neuroscience (SCAF), these 2 
projects are complementary.
The 3 articles in this theme are the first batch of pub-
lications from the SCAF project. As the project is still 
ongoing, future articles will capitalize on the larger sam-
ple sizes, eg, by using structural equation modeling. The 
primary psychometric and external validity data, how-
ever, are contained in the articles in this theme.
The first article presents the conceptual foundation 
for the SCAF project, and it describes the process used 
to guide the selection of the domains and paradigms.11 
This article places these activities and data in the larger 
context of intervention trials. It also describes the selec-
tion criteria that were used to arrive at a small number 
of experimental paradigms from social neuroscience, and 
the current knowledge of the neural substrates of those 
paradigms.
The second article is a detailed psychometric evalu-
ation of the paradigms with samples of patients with 
schizophrenia and healthy controls.12 In this article, we 
present findings for test-retest reliability, between-group 
effect sizes, utility as a repeated measure (including prac-
tice effects), issues of scale attenuation (floor and ceiling 
effects), practicality, and tolerability. These data indicate 
the degree to which the measures are suitable for multisite 
clinical trials on each of these factors.
The third article in this theme examines the external 
validity of the measures.13 Specifically, we consider how 
well the measures relate to functional capacity and com-
munity outcome. We also examine the measures’ incremen-
tal validity—the extent to which they explain variance in 
functioning beyond that provided by a standard social cog-
nitive measure of facial affect identification and beyond 
nonsocial cognition. These relationships are important to 
understand because social cognition may be more proxi-
mal (in terms of a causal pathway) to daily functioning 
than are perceptual and nonsocial cognitive processes.14
Taken together, the articles in this theme offer 1 model 
of how to identify and evaluate paradigms from novel 
research areas for use with clinical psychiatric disorders. 
The problems we encountered apply equally well to adapt-
ing measures from other areas of basic science; social neu-
roscience, however, provides a good test case. The articles 
in this theme provide a summary of the theoretical basis 
for the paradigms we selected, as well as psychometric 
and validity data that can be used by clinical trialists when 
designing clinical trials. As more studies examine social 
cognition in schizophrenia and other psychotic disorders, 
and as more studies evaluate training and psychopharma-
cological interventions for social cognition, the articles in 
this theme are intended to serve as a guide for informed 
decisions about relevant social cognitive domains and 
potential endpoints for treatment studies.
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